<DOC>
	<DOC>NCT00115518</DOC>
	<brief_summary>The purpose of this trial is to study combined locoregional radiotherapy with cetuximab in non-operable NSCLC Stage III (Phase II trial). Endpoints: safety and feasibility (primary) response, survival, time to progression (secondary)</brief_summary>
	<brief_title>Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description>Study entry examinations: - blood cell count - liver enzymes - ventilatory function test - pregnancy test (premenopausal women) - CT of the thorax - CT of the brain - Ultrasound of the liver - Bone scan - FDG PET scan (after inclusion) Follow-up examinations (2 months, than every 3 months): - patients history and examination - CT scan of the thorax - ventilatory functions test - FDG PET scan (at least at 6 months) - bone scan (yearly) - ultrasound of the liver (every 6 months) Cetuximab administration: - 450 mg / m^2 body surface on week 1 - 250 mg /m^2 body surface weekly, week 2 -21 Radiation therapy: - intensity modulated radiation therapy of primary tumor and mediastinum (2 Gy single dose, total dose 50 Gy; 5 fractions per week) with boost to the PET positive sites (2 Gy single doses up to 66 Gy). Radiation therapy during weeks 2-8. Amendment 1/07: 3D conformal RT possible, but not if FeV1 &lt; 1.5L of &lt; 50%</detailed_description>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically verified NSCLC Not eligible for Radiochemotherapy or patient refuses chemotherapy FeV1 &gt;1.5 L or min. 50% KPI &gt;= 70% Life expectancy &gt; 6 months Weight loss less than 10% of body weight in 12 months Compliance Adequate blood counts (LC &gt; 3000 x 10^3/ml, Tc &gt;100000 x 10^3/ml, Hb &gt; 10 g/dl) Effective contraception Amendment 1/07: FeV1 &gt;1.2 L or min 40% Active infection Reduced liver function Vena cava superior syndrome Malignant pleural effusion Pregnancy or breast feeding Additional serious systemic disease Secondary malignancy (except carcinoma in situ of the cervix, basalioma of the skin, secondary cancer in remission for &gt; 5 years) Known allergies against proteins History of former antibody therapy Allergy against i.v. contrast agents</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>